1. A Knockout Combo: Eradicating AML Stem Cells with TKI plus SIRT1 Inhibition
- Author
-
Bernd B. Zeisig and Chi Wai Eric So
- Subjects
Myeloid ,endocrine system diseases ,Cell ,Cancer ,Imatinib ,Cell Biology ,Biology ,medicine.disease ,enzymes and coenzymes (carbohydrates) ,Leukemia ,medicine.anatomical_structure ,Cancer stem cell ,hemic and lymphatic diseases ,Combination cancer therapy ,Immunology ,Genetics ,medicine ,Cancer research ,Molecular Medicine ,Stem cell ,neoplasms ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. In this issue of Cell Stem Cell, Li et al. (2014) demonstrate a similar role for SIRT1 inhibition in eradicating FLT3-ITD AML stem cells, potentially through a positive feedback loop with c-MYC, highlighting SIRT1 as a potential target in combination cancer therapy.
- Published
- 2014